AstraZeneca PLC Ordinary Shares (AZN)

FairStock Score: 61/100 — STEADY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for a durable business bought at a sensible price. AstraZeneca is a large biopharmaceutical company with a broad list of prescription medicines, 96,100 employees, and a market capitalization of $302.1B at the 2026-10-13 close. The latest reported quarter, 2026-Q2, showed revenue of $15.4B, net income of $2.5B, and a 16.30% margin. That is a real business, not a story. The balance sheet looks reasonable: debt-to-equity is 0.64, Altman Z-Score is 3.11, and ROE is 21.96% on FairStock's calculation. But ROCE is only 8.02%, so returns on total capital are less impressive. Free cash flow is $6.0B trailing twelve months, a 2.0% FCF yield; for a $302B company, that is thin. Growth in the provided figures looks modest. The valuation is not Graham-like. At $155.82, the P/E is 23.33, P/B is 4.80, and the Graham Number is $69.82, leaving a margin of safety of -123.17%. The PEG ratio of 10.01 suggests the price is high relative to growth. A 1.93% dividend and beta of 0.20 add defensiveness, but they do not make the shares cheap. The Piotroski F-Score is 5/9, middling, and the FairStock Score is 60/100. My conclusion: a quality drugmaker, but the price already reflects much of the good news; I would want a wider discount before calling it a bargain.

In plain English: AstraZeneca is a big maker of prescription medicines. The business is profitable and has a strong balance sheet, but its profits are growing slowly and it produces less cash than you might expect for its size. The share price looks high compared with what the company earns and owns.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer